Nautilus Biotechnology (NAUT) Research & Development (2020 - 2026)
Nautilus Biotechnology (NAUT) posted Research & Development of $9.6 million for Q2 2026, down 0.97% sequentially from $9.7 million in Q1 2026, and down 7.51% YoY from $10.4 million in Q2 2025.
Nautilus Biotechnology (NAUT) Research & Development (2020 - 2026) Analysis & Trends
Nautilus Biotechnology has reported Research & Development for 7 years, with the latest figure at $9.6 million in Q2 2026.
- Quarterly Research & Development fell 7.51% year-over-year to $9.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $38.5 million (down 18.16% YoY) and the FY2025 annual result came in at $41.1 million, down 18.56% from the prior year.
- Research & Development slipped to $9.6 million in Q2 2026 per NAUT's latest filing, from $9.7 million in the prior quarter.
- Over five years, Research & Development peaked at $12.9 million in Q1 2024 and troughed at $8.9 million in Q2 2022.
- A 5-year average of $10.9 million and a median of $10.6 million in 2023 frame the typical range for Research & Development.
- The sharpest annual moves came in 2022 and 2025: Research & Development jumped 99.75% in 2022, then fell 25.33% in 2025.
- Over 5 years, Research & Development stood at $9.6 million in 2022, then jumped by 30.03% to $12.5 million in 2023, then gained by 2.86% to $12.8 million in 2024, then dropped by 25.33% to $9.6 million in 2025, then climbed by 0.4% to $9.6 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $9.6 million, $9.7 million, and $9.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Nautilus Biotechnology | 114.43 Mn | 114.43 Mn | 175,000.00 | 9.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.61 Mn |
| Mar 31, 2026 | 9.71 Mn |
| Dec 31, 2025 | 9.58 Mn |
| Sep 30, 2025 | 9.61 Mn |
| Jun 30, 2025 | 10.39 Mn |
| Mar 31, 2025 | 11.54 Mn |
| Dec 31, 2024 | 12.82 Mn |
| Sep 30, 2024 | 12.29 Mn |
| Jun 30, 2024 | 12.44 Mn |
| Mar 31, 2024 | 12.93 Mn |
| Dec 31, 2023 | 12.47 Mn |
| Sep 30, 2023 | 12.00 Mn |
| Jun 30, 2023 | 11.91 Mn |
| Mar 31, 2023 | 10.88 Mn |
| Dec 31, 2022 | 9.59 Mn |
| Sep 30, 2022 | 9.57 Mn |
| Jun 30, 2022 | 8.86 Mn |
| Mar 31, 2022 | 9.66 Mn |
| Dec 31, 2021 | 9.89 Mn |
| Sep 30, 2021 | 8.24 Mn |